With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Twelve new studies released by the American Journal of Clinical Nutrition continue to underscore the benefits of tea, from ...

Metabolic healthcare—encompassing conditions such as diabetes, obesity, and hypertension—has become a global health crisis.

Subcutaneous semaglutide 2.4mg is currently marketed under the brand name Wegovy for chronic weight management in adults and pediatric patients and to reduce the risk of major adverse ...

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

Carrying excess weight places significant strain on the cardiovascular system, increasing risks of life-threatening conditions like stroke and heart attack.